The largest database of trusted experimental protocols

8 protocols using accucount blank particles

1

CLL Chemotaxis Assay Across Transwell

Check if the same lab product or an alternative is used in the 5 most similar protocols
Chemotaxis assays across polycarbonate Transwell inserts were performed as previously described (24 (link)). Briefly, 106 CLL PBMCs in AIM-V medium (Gibco) were transferred into the top chambers of Transwell culture inserts (Corning Incorporated) with a diameter of 6.5 mm and a pore size of 5 µm. Filters were then placed into wells containing medium (control), medium with 200 ng/mL CXCL12 and 100 ng/mL CCL19 (Prospec) or a mixture of 50% medium and 50% bone marrow supernatant collected pre-treatment. Where indicated, cells were pre-incubated with 1µM ibrutinib (Sellekchem) in vitro for 1 hour. CLL PBMCs were allowed to migrate for 3 hours at 37°C. Migrated cells in the lower chamber were collected, stained with CD19 and CD3 and counted using AccuCount blank particles (Spherotech) as previously described (25 (link)). The migration index was determined by subtracting the percent migration of the medium control from the percent migration of the chemotractant wells and normalizing. Migration experiments were performed in triplicate plates; results are reported as the average.
+ Open protocol
+ Expand
2

Tumor Burden and Cell Viability Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
To determine tumor burden and the percentage of live cells, PBMCs and tissue-derived, single-cell suspensions were stained with LIVE/DEAD fixable violet solution (VIVID; Invitrogen, Grand Island, NY, USA) and Annexin-V (BD Biosciences, Franklin Lakes, NJ, USA) according to manufacturer’s instructions. Mouse anti- CD45R/B220 and CD5 were used to identify TCL1-192 cells. Determination of absolute cell counts was done using AccuCount blank particles (Spherotech, Lake Forest, IL, USA). Intracellular staining was done as previously described.(3 (link)) Briefly, cells were fixed in 4% paraformaldehyde, permeabilized in 90% methanol or 80% ethanol at −20°C and stained with surface antibodies and intracellular stains. Intracellular stains included anti- Ki67, phospho-PLCγ2(Y759), phospho-ERK1/2(T202/Y204) and phospho-p65(S529) (BD Biosciences). Cut-off for positive cells was determined by isotype controls. Cells were analyzed on a FACS Canto II flow cytometer using FACS-DIVA (BD Biosciences) and FlowJo software (version 9; TreeStar, Ashland, OR, USA). For some experiments, cells were barcoded with different concentrations of pacific orange and pacific blue (Invitrogen) to allow for analysis of multiple samples in one tube.(21 (link))
+ Open protocol
+ Expand
3

NK Cell-Mediated Cytotoxicity Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
NK cell-mediated CD4+ T cell cytotoxicity was assessed by flow cytometry. Briefly, purified CD4+ T cells from the same healthy control donor were co-cultured with or without purified NK cells at a 1:3 ratio in 96-well V-bottom plates (Corning). Cells were incubated for 15 min at room temperature, spun at 300 g for 1 min, and incubated for 6 h at 37°C. After incubation, cells were surface stained with antibodies against CD3, and fixed with 2% paraformaldehyde solution containing a constant number of flow cytometry particles (5*104/ml) (AccuCount blank particles, 5.3 μm; Spherotech, Lake Forest, IL). A constant number of particles (2.5*103) were counted during cytometry acquisition in order to normalize the number of CD4+ T cells. The percentage of CD4+ T cell cytolysis was calculated using the formula: %cytolysis = [(number of CD3+ T cells in the absence of NK cells)–(number of CD3+ T cells in the presence of NK cells)]/(number of CD3+ T cells in the absence of NK cells) *100.
+ Open protocol
+ Expand
4

Quantifying CLL Cell Migration Towards Bone Marrow Supernatant

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMCs collected pre-treatment were evaluated for their ability to migrate towards patient matched BM supernatant collected either pre-treatment or on ibrutinib. Chemotaxis assays across polycarbonate Transwell inserts were performed as previously described.(35 (link)) 106 pre-treatment CLL PBMC cells in AIM-V medium (Gibco) were transferred into the top chambers of Transwell culture insert (Corning Incorporated) with a diameter of 6.5 mm and a pore size of 5 μm. Filters were then placed onto wells containing medium (control) or a mixture of 50% medium and 50% bone marrow supernatant collected either pre-treatment or after eight weeks on ibrutinib. CLL PBMC were allowed to migrate for 3 hours at 37°C. Migrated cells in the lower chamber were then collected and counted in triplicates using AccuCount blank particles (Spherotech) to quantify the absolute number of input and migrated B and T cells stained with CD19 and CD3 as previously described.(2 (link)) The migration index was determined by subtracting the medium control percentage migration from the chemoattractant percentage migration and normalizing.
+ Open protocol
+ Expand
5

Quantifying Leukocyte Infiltrates in Brain Injury

Check if the same lab product or an alternative is used in the 5 most similar protocols
Immediately following tissue processing described above, cell suspensions from the brain, galea, and bone flap were treated with TruStain FcX (BioLegend Cat# 101320, RRID:AB_1574975) to prevent nonspecific antibody binding. A 5-color Ab panel was used to quantify leukocyte infiltrates that included CD45-APC (RRID:AB_312977), CD11b-FITC (RRID:AB_312789), Ly6G-PacBlue (BioLegend, Cat# 127612), Ly6C-PerCP-Cy5.5 (BD Biosciences, Cat# 560525), and F4/80-PECy7 (RRID:AB_893478). Nonviable cells were excluded from analysis using a Zombie UV Fixable Viability Kit (BioLegend, Cat# 423108), and samples were processed with a BD LSRII Green cytometer. Spherotech AccuCount Blank Particles (Cat# ACBP-100-10; 8.0-12.9 μm) were used to report absolute cell counts. Samples were analyzed with FlowJo (RRID:SCR_008520) using the gating strategy presented in Supplemental Fig. 1.
+ Open protocol
+ Expand
6

Cytotoxicity Evaluation of Leukemia Drugs

Check if the same lab product or an alternative is used in the 5 most similar protocols
To evaluate the cytotoxicity of ASNase, vincristine (VCR), and daunorubicin (DNR), MTS (dimethylthiazol carboxymethoxyphenyl sulfophenyl tetrazolium) assays were performed using a CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega Corporation, Wisconsin, USA) according to the manufacturer’s instructions and our previous publication [7 (link)]. Range of ASNase concentration used in the MTS assay was 0 - 4 IU/ml (5-fold dilutions), for VCR it was 0 - 50 nM (5-fold dilutions) and 0 - 3 μM (5-fold dilutions) for DNR. We seeded 1.2 × 104 cells of leukemia cell lines and 1 × 105-3 × 105 patient cells. To evaluate the combined cytotoxicity of the 2 drugs, the number of live cells was determined by flow cytometry using DAPI (ThermoFisher Scientific Inc., MA, USA) and AccuCount Blank Particles (Spherotech Inc., IL, USA). The MTS assay was performed in at least 3 independent experiments. Cell counts were done in biological triplicates.
+ Open protocol
+ Expand
7

Antibody-Dependent Cytolysis Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
As previously described [31, 35] , the antibody-pendent cytolysis of 8E5 cells by PBMCs from different donors was assessed by flow cytometry. Briefly, 8E5 cells were stained with the viability dye AquaVivid (Invitrogen) and eFluor670 cellular marker (eBioscience, San Diego, California, USA), whereas PBMCs were labeled with the eFluor450 cellular marker (eBioscience). Effector cells were combined with targets in the presence of the indicated antibody (10 nmol/l) and incubated for 4-5 h at 37 °C. Following incubation, cells were then fixed with a 2% PBS-formaldehyde solution containing a constant number of flow cytometry particles (5 × 10 4 /ml; AccuCount blank particles, 5.3 μm; Spherotech Inc., Lake Forest, Illinois, USA). Samples were collected on an LSRFortessa flow cytometer (BD Biosciences) and analyzed with FlowJo (TreeStar, San Carlos, California, USA). Supplemental Figure S1, https://links.lww.com/QAD/B279 shows the gating strategy and formula allowing the calculation of antibody-dependent cytotoxicity.
+ Open protocol
+ Expand
8

Quantifying E. coli Cell Growth

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell growth was determined as the ratio of cells per defined volume of counting particles (2 μm AccuCount Blank Particles). For this, 79 μL of 50 µg/ml Tc and 500 μg/mL rifampicin (Sigma-Aldrich Chemie GmbH) in phosphate-buffered saline for transcription and translation inhibition, and 21 μL of AccuCount Blank Particles (Spherotech) for counting reference was used per sample. The cell solution was added in equal volumes (100 µL cell culture to 100 µL of inhibition and counting solution). Absolute cell counts per particle counts were determined by flow cytometry. For this, samples were measured for 2 min at 10 µL/min. The gating of the AccuCount particles and cells is shown in Supplementary Fig. 12 bottom. The reported data are from three biological replicates pooled from experiments performed on the same day. The doubling time of E. coli was measured to be 36.9 ± 1.2 min in our setup (Supplementary Fig. 13). We further determined that an inoculum of 1:20,000 of overnight culture into fresh media leads to an OD600 of 0.034 ± 0.003 after 5 h incubation, therefore ensuring logarithmic growth throughout the experiments. Further, a calibration of optical density of a cell culture (OD600) to our cell growth measurement using flow cytometry (counts/bead) was performed, which shows a linear correlation until an OD600 of 0.2 (Supplementary Fig. 14).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!